v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total income and other revenues $ 674,141 $ 578,665 $ 1,304,717 $ 1,146,912
Operating expense/(income)        
Provision for changes in expected cash flows from financial royalty assets 268,216 (203,938) 70,732 (331,078)
Provision for credit losses on unfunded commitments 13,068 92,535 9,368 92,535
Research and development funding expense 97,851 300,500 137,641 351,000
General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4) 161,887 179,769 321,377 290,475
Financial royalty asset impairment 0 0 69,443 0
Total operating expense, net 541,022 368,866 608,561 402,932
Operating income 133,119 209,799 696,156 743,980
Other (income)/expense        
Equity in earnings of equity method investees (4,077) (2,693) (25,835) (9,136)
Interest expense 93,617 68,668 187,339 133,929
(Gains)/losses on equity securities (69,156) 30,553 (48,990) 76,431
Losses on available for sale debt securities 34,880 27,420 41,560 30,701
Interest income (5,127) (8,327) (11,356) (19,617)
Other non-operating expenses, net 1,496 1,543 3,697 4,604
Total other expense, net 51,633 117,164 146,415 216,912
Consolidated net income before tax 81,486 92,635 549,741 527,068
Income tax expense 0 0 0 0
Consolidated net income 81,486 92,635 549,741 527,068
Net income attributable to non-controlling interests 63,603 60,459 237,169 255,543
Net income attributable to Royalty Pharma plc $ 17,883 $ 32,176 $ 312,572 $ 271,525
Earnings per Class A ordinary share:        
Basic (in dollars per share) $ 0.04 $ 0.08 $ 0.71 $ 0.63
Diluted (in dollars per share) $ 0.04 $ 0.07 $ 0.71 $ 0.63
Weighted average Class A ordinary shares outstanding:        
Basic (in shares) 445,064 423,514 440,950 429,464
Diluted (in shares) 556,896 562,298 557,352 570,157
Income from financial royalty assets        
Total income and other revenues $ 638,027 $ 550,418 $ 1,233,019 $ 1,089,908
Other royalty income and revenues        
Total income and other revenues $ 36,114 $ 28,247 $ 71,698 $ 57,004